• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Class 2 Device Recall ETEST Ciprofloxacin

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
  Class 2 Device Recall ETEST Ciprofloxacin see related information
Date Initiated by Firm December 15, 2016
Date Posted March 21, 2017
Recall Status1 Terminated 3 on August 18, 2020
Recall Number Z-1524-2017
Recall Event ID 76201
510(K)Number K981138  
Product Classification Manual antimicrobial susceptibility test systems - Product Code JWY
Product Ciprofloxacin CI 32 Foam packaging, Product Name: ETEST Ciprofloxacin CI 0.002-32.
ETEST is a quantitative technique for determining the antimicrobial susceptibility of Gram-negative and Gram-positive aerobic bacteria such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Enterococcus species and fastidious bacteria, such as anaerobes, N. gonorrhoeae, S. pneumoniae, Streptococcus and Haemophilus species. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC), in ¿g/mL, of different antimicrobial agents against microorganisms as tested on agar media using overnight incubation. Current Antimicrobial Susceptibility Testing (AST) methods are based either on quantitative dilution techniques or qualitative diffusion procedures. Dilution methods are based on two-fold serial dilutions of antibiotics in broth or agar media. These methods generate the MIC value i.e. Minimum Inhibitory Concentration of a given antibiotic in ¿g/mL that will inhibit the growth of a particular bacterium under defined experimental conditions
Code Information Reference no. 508650, Lot #1001060450, 1001154650, 1001212890, 1001264540, 1001319180, 1001390080, 1001390440, 1001409510, 1001409520, 1001441760, 1001540660, 1001589490, 1001621240 & 1001656460; Reference no. 508658, Lot #1001093880, 1001154820, 1001265110, 1001319480, 1001390570, 1001441910, 1001487610, 1001647880, 1001708510, 1001811360, 1002041010, 1002102920, 1002435570, 1002567240, 1002725010, 1003246020, 1003889730, 1004168400, 1004364330, 1004491220 & 1004939670; Reference no. 508610, Lot #1001026950, 1001199360 1001427690, 1001518090, 1001595490, 1001740320 & 1001989260 and Reference no. 508618, Lot #1001032350, 1001242030, 1001338050, 1001416820, 1001471720, 1001595500, 1001627650, 1001720440, 1001728140, 1001786480, 1001956220, 1002109250, 1002338880, 1002435190, 1002566960, 1002718380, 1002975330, 1003886270, 1003894060, 1003981160, 1004064990, 1004075190, 1004168390, 1004490810 & 1004939640.
Recalling Firm/
BioMerieux SA
Chemin De L'Orme
Marcy L'Etoile France
For Additional Information Contact Tiffany Mentzel
Manufacturer Reason
for Recall
Product Stability issues: The current shelf-life claims of the ETEST products are not supported by internal testing.
FDA Determined
Cause 2
Action biomerieux sent an Urgent Field Safety Notice dated December 15, 2016, to all affected consignees. The letter identified the product, the problem, and the action to be taken by the consignee. Consignees were instructed to identify the affected lots and immediately order the replacement products. Laboratories should continue to follow their current QC procedures. When replacement product is received, consignees should discontinue using any discard affected product. Consignees should distribute this information to all appropriate personnel in their laboratory, retain a copy in their files, and forward the information to all parties that may use this product, including others to whom they may have transferred our product. Consignees should contact their bioMerieux representative for product compensation. Consignees should also complete and return the Acknowledgment Form in Attachment A by Fax to confirm receipt of the notice. Consignees with questions should contact their local bioMerieux Clinical Customer Service representative. For questions regarding this recall call 314-731-8516.
Quantity in Commerce unknown
Distribution Worldwide Distribution - U.S.( Nationwide); Foreign: Utd.Arab Emir., Argentina, Austria, Australia, Brazil, Canada, Switzerland, Chile, Colombia, Czech Republic, Germany, Algeria, Spain, France, United Kingdom, Greece, Hong Kong, India, Italy, Japan, South Korea, Mexico, Netherlands, Poland, Portugal, Russian, Fed. Sweden, Singapore, Thailand, Turkey, South Africa, Indonesia, Peru, Saudi Arabia, Gabon, Kazakhstan, Philippines, Ivory Coast, Venezuela, Kenya, Serbia, Tunisia, Macedonia, Lebanon, Romania, Benin, Bosnia-Herz., Oman, Uruguay, Lithuania, Burkina Faso, Slovenia, Qatar, Kuwait, Costa Rica, Paraguay, Dominican Republic, Croatia, Panama, Congo, Dem. Rep. Congo, Honduras, Estonia, Latvia, Cambodia, Bulgaria, Vietnam, Dutch Antilles, Nicaragua, Israel, Georgia, Palestine, Egypt, Pakistan (includ.Afghanistan), Malta, Jordan Bahrain, El Salvador, Nigeria, Dutch Antilles, Iran, Belarus, Zimbabwe, Morocco, Mauretania, Anguilla, Philippines, Malaysia, Turkmenistan, Guam, Brunei, Bolivia, Guatemala, Ecuador, Belarus, Mongolia
Total Product Life Cycle TPLC Device Report

1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.
510(K) Database 510(K)s with Product Code = JWY and Original Applicant = AB BIODISK